PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), the United States federal government’s principal agency for cancer research and training, has awarded the Company a research grant of $2,054,651 to advance Bria-PROS+, BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer.
Related Questions
How will the $2 million NCI grant impact BriaCell’s cash runway and potential dilution for shareholders?
What is the anticipated timeline for clinical milestones of Bria‑PROS+ in prostate cancer, and how might those milestones affect the stock price?
How does Bria‑PROS+ compare to competing prostate‑cancer immunotherapies, and does this grant give BriaCell a competitive advantage?